@article{572f05d1af8f4b5b82f3594c54c8b443,
title = "Retreatment with brentuximab vedotin in CD30‑positive hematologic malignancies: A phase II study.",
author = "Nancy Bartlett and Pauline Brice and Chen, \{Robert W.\} and Fanale, \{Michelle A.\} and Gopal, \{Ajay K.\} and Jeffrey Matous and Rosenblatt, \{Joseph David\} and Grove, \{Laurie E.\} and Andres Forero-Torres",
note = "8027 Background: Brentuximab vedotin comprises an anti-CD30 antibody conjugated by a protease-cleavable linker to a microtubule-disrupting agent, MMAE. In pivotal phase 2 studies in patients (pts) with relapsed/refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL), objective response rates were 75\% and 86\% and median durations of response were 6.7 and 12.6 mo, respectively.",
year = "2012",
month = may,
day = "20",
doi = "10.1200/JCO.2012.30.15\_SUPPL.8027",
language = "American English",
volume = "30",
journal = "Journal of Clinical Oncology",
}